US FDA’s ‘Platform’ Pathway Fits For LNPs And siRNA But Not Delivery Devices

 
• By Michael McCaughan
  
diving platform
Monoclonal antibody platforms also are among the technologies that could receive a platform designation from the FDA. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Pathways & Standards